Shares of Idenix Pharmaceuticals (IDIX +32.8%) are on-the-move this morning, trading sharply higher on heavy volume.
Although there are no readily apparent catalysts for the move, the company did give an HCV pipeline update Wednesday along with its Q3 report.
Summary: Enrollment initiated for IDX21437 Phase 1/2, enrollment complete in HELIX-1 (that's the samatasvir/ simeprevir/ ribavirin GT1b and GT4 trial) with SVR4 data expected in Q4.
Also of note, IDIX said its cash "will be sufficient to sustain its operations through December 2014." (PR)